Henatinib

DB13019InvestigationalSmall molecule

Henatinib has been used in trials studying the treatment of Advanced Solid Cancer.

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor 2
Curator reviewed
Formula / weight: C₂₅H₂₉FN₄O₄ · 468.529 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyMCTXSDCWFQAGFS-UEXNTNOUSA-NSMILESCC1=C(NC2=C1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2)\C=C1/C(=O)NC2=CC=C(F)C=C12

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Henatinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.